Intermediate-dose methotrexate and cisplatin in the treatment of advanced epidermoid esophageal carcinoma. Response rate and disease-free survival

T. K. Saikia, S. H. Advani, G. Ramakrishnan, Santhi Swaroop Vege, S. Sharma, P. B. Desai

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Seventeen patients with inoperable locoregional disease (epidermoid carcinoma of the esophagus) were treated only with two courses of intermediate-dose methotrexate (200 mg/m2 on day 1) and cisplatin (20 mg/m2/d for 5 days). According to the response criteria, 14 (82.4%) achieved a good response (GR) and 3 (17.6%) showed no response (NR). The median recurrence-free survival time was 5 months (range, 2 to 16 months) in seven patients with regular follow-up. Three patients are still alive and disease-free at 37+, 44+, and 51+ months. No patient received radiotherapy or surgery after chemotherapy until recurrence. This combination schedule appears to be effective in advanced esophageal carcinoma.

Original languageEnglish (US)
Pages (from-to)371-373
Number of pages3
JournalCancer
Volume64
Issue number2
StatePublished - 1989
Externally publishedYes

Fingerprint

Methotrexate
Cisplatin
Disease-Free Survival
Squamous Cell Carcinoma
Recurrence
Therapeutics
Esophagus
Appointments and Schedules
Radiotherapy
Carcinoma
Drug Therapy
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Intermediate-dose methotrexate and cisplatin in the treatment of advanced epidermoid esophageal carcinoma. Response rate and disease-free survival. / Saikia, T. K.; Advani, S. H.; Ramakrishnan, G.; Vege, Santhi Swaroop; Sharma, S.; Desai, P. B.

In: Cancer, Vol. 64, No. 2, 1989, p. 371-373.

Research output: Contribution to journalArticle

Saikia, T. K. ; Advani, S. H. ; Ramakrishnan, G. ; Vege, Santhi Swaroop ; Sharma, S. ; Desai, P. B. / Intermediate-dose methotrexate and cisplatin in the treatment of advanced epidermoid esophageal carcinoma. Response rate and disease-free survival. In: Cancer. 1989 ; Vol. 64, No. 2. pp. 371-373.
@article{fed232027c3a4b25bc1b134228c0a48f,
title = "Intermediate-dose methotrexate and cisplatin in the treatment of advanced epidermoid esophageal carcinoma. Response rate and disease-free survival",
abstract = "Seventeen patients with inoperable locoregional disease (epidermoid carcinoma of the esophagus) were treated only with two courses of intermediate-dose methotrexate (200 mg/m2 on day 1) and cisplatin (20 mg/m2/d for 5 days). According to the response criteria, 14 (82.4{\%}) achieved a good response (GR) and 3 (17.6{\%}) showed no response (NR). The median recurrence-free survival time was 5 months (range, 2 to 16 months) in seven patients with regular follow-up. Three patients are still alive and disease-free at 37+, 44+, and 51+ months. No patient received radiotherapy or surgery after chemotherapy until recurrence. This combination schedule appears to be effective in advanced esophageal carcinoma.",
author = "Saikia, {T. K.} and Advani, {S. H.} and G. Ramakrishnan and Vege, {Santhi Swaroop} and S. Sharma and Desai, {P. B.}",
year = "1989",
language = "English (US)",
volume = "64",
pages = "371--373",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Intermediate-dose methotrexate and cisplatin in the treatment of advanced epidermoid esophageal carcinoma. Response rate and disease-free survival

AU - Saikia, T. K.

AU - Advani, S. H.

AU - Ramakrishnan, G.

AU - Vege, Santhi Swaroop

AU - Sharma, S.

AU - Desai, P. B.

PY - 1989

Y1 - 1989

N2 - Seventeen patients with inoperable locoregional disease (epidermoid carcinoma of the esophagus) were treated only with two courses of intermediate-dose methotrexate (200 mg/m2 on day 1) and cisplatin (20 mg/m2/d for 5 days). According to the response criteria, 14 (82.4%) achieved a good response (GR) and 3 (17.6%) showed no response (NR). The median recurrence-free survival time was 5 months (range, 2 to 16 months) in seven patients with regular follow-up. Three patients are still alive and disease-free at 37+, 44+, and 51+ months. No patient received radiotherapy or surgery after chemotherapy until recurrence. This combination schedule appears to be effective in advanced esophageal carcinoma.

AB - Seventeen patients with inoperable locoregional disease (epidermoid carcinoma of the esophagus) were treated only with two courses of intermediate-dose methotrexate (200 mg/m2 on day 1) and cisplatin (20 mg/m2/d for 5 days). According to the response criteria, 14 (82.4%) achieved a good response (GR) and 3 (17.6%) showed no response (NR). The median recurrence-free survival time was 5 months (range, 2 to 16 months) in seven patients with regular follow-up. Three patients are still alive and disease-free at 37+, 44+, and 51+ months. No patient received radiotherapy or surgery after chemotherapy until recurrence. This combination schedule appears to be effective in advanced esophageal carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0024364627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024364627&partnerID=8YFLogxK

M3 - Article

C2 - 2736483

AN - SCOPUS:0024364627

VL - 64

SP - 371

EP - 373

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -